{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:52:33Z","timestamp":1781693553451,"version":"3.54.5"},"reference-count":19,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Quality of life (QoL) has become an essential outcome in patients with metastatic prostate cancer, particularly in the era of androgen receptor (AR)-targeted therapies. Although these agents improve survival, their differential impact on QoL and the role of psychological factors remain incompletely understood. This study aimed to evaluate QoL, functional outcomes, and psychological status, and to identify factors associated with poor QoL in a real-world cohort. Materials and Methods: This prospective cross-sectional, single-center observational study included 130 patients with metastatic prostate cancer receiving AR-targeted therapies (abiraterone, enzalutamide, or apalutamide\/darolutamide). QoL was assessed using the EORTC QLQ-C30 questionnaire, and psychological status was evaluated using the Hospital Anxiety and Depression Scale (HADS). Patients were stratified according to treatment groups, and comparisons were performed using appropriate statistical tests. Logistic regression analyses were conducted to determine factors independently associated with poor QoL. Results: Exploratory differences in global QoL were observed among treatment groups (p = 0.007), with lower global QoL scores in the abiraterone group and numerically higher emotional and cognitive functioning scores in the enzalutamide group. Symptom analysis demonstrated higher nausea\/vomiting scores in the abiraterone group (p = 0.022), whereas other symptom domains were comparable across treatment groups. In multivariable analysis, anxiety (odds ratio [OR]: 6.62) and depression (OR: 3.40) were independently associated with poor QoL, while treatment type was not independently associated with poor QoL after multivariable adjustment. Conclusions: Although unadjusted QoL scores differed across AR-targeted therapy groups, psychological factors\u2014particularly anxiety and depression\u2014were significantly associated with poorer QoL in patients with metastatic prostate cancer. These findings highlight the importance of integrating routine psychosocial assessment and supportive care strategies into clinical practice to optimize patient-centered outcomes. However, given the cross-sectional and exploratory nature of the study, the findings should be interpreted cautiously.<\/jats:p>","DOI":"10.3390\/medicina62061175","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:22:56Z","timestamp":1781684576000},"page":"1175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of Life and Psychological Factors in Patients with Metastatic Prostate Cancer Receiving Androgen Receptor\u2013Targeted Therapies: A Prospective Cross-Sectional Real-World Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-2633","authenticated-orcid":false,"given":"Selahattin","family":"\u00c7elik","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Training and Research Hospital, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-1606","authenticated-orcid":false,"given":"Salih","family":"Karatl\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Training and Research Hospital, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-2079","authenticated-orcid":false,"given":"Mehmetcan","family":"Atak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Training and Research Hospital, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-5861","authenticated-orcid":false,"given":"Hatice Ayy\u0131ld\u0131z","family":"Sevim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Training and Research Hospital, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6k\u015fen \u0130nan\u00e7","family":"\u0130mamo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Training and Research Hospital, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-7429","authenticated-orcid":false,"given":"Samed","family":"Rahatl\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Etlik City Training and Research Hospital, 06010 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2014.72","article-title":"Evolution of androgen receptor targeted therapy for advanced prostate cancer","volume":"11","author":"Wong","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41391-023-00668-0","article-title":"Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: The role of combination treatment therapy","volume":"27","author":"Afferi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"k1415","DOI":"10.1136\/bmj.k1415","article-title":"Depression and anxiety in patients with cancer","volume":"361","author":"Pitman","year":"2018","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1200\/JCO.2011.40.8922","article-title":"Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: Systematic review and meta-analysis","volume":"31","author":"Faller","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: Neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/SLA.0b013e31822a7047","article-title":"Cancer trials versus the real world in the United States","volume":"254","author":"Vickers","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41391-021-00359-8","article-title":"Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: A systematic review and meta-analysis","volume":"24","author":"Ternov","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18433\/jpps31003","article-title":"Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis: Abiraterone versus enzalutamide in mCRPC","volume":"23","author":"Wang","year":"2020","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41391-020-00286-0","article-title":"Depression, anxiety, and suicidality in patients with prostate cancer: A systematic review and meta-analysis of observational studies","volume":"24","author":"Brunckhorst","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1037\/a0035730","article-title":"Biobehavioral approaches to cancer progression and survival: Mechanisms and interventions","volume":"70","author":"Lutgendorf","year":"2015","journal-title":"Am. Psychol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jamaoncol.2025.3153","article-title":"Patient-reported outcomes as prognostic indicators for overall survival in cancer: A systematic review and meta-analysis","volume":"11","author":"Huang","year":"2025","journal-title":"JAMA Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:01:27Z","timestamp":1781690487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061175"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061175","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}